超声引导微波消融治疗原发性甲状旁腺功能亢进症的安全性与有效性研究
研究纳入22例原发性甲状旁腺功能亢进症患者,于2014年11月1日至2016年2月29日接受超声引导下微波消融辅助持续冷盐水注射治疗。19例(86.36%)患者甲状旁腺激素和血钙均恢复正常,术后6个月平均甲状旁腺激素和血钙均较术前显著降低(均p<0.05)。8例出现暂时性声音改变,1例低钙血症经口服补钙2个月内纠正;作者认为该技术安全有效,可能作为治疗选择。
要点
- 超声引导微波消融辅助持续冷盐水注射可使86.36%(19/22)的原发性甲状旁腺功能亢进症患者甲状旁腺激素和血钙恢复正常。
- 术后6个月平均甲状旁腺激素和平均血钙均较术前显著降低(均p<0.05)。
- 8例出现暂时性声音改变,1例低钙血症经口服补钙2个月内纠正。
核心结论
- 超声引导微波消融辅助持续冷盐水注射可安全有效地破坏甲状旁腺组织,可能作为原发性甲状旁腺功能亢进症患者的治疗替代选择。
研究设计与样本
- 研究纳入2014年11月1日至2016年2月29日期间22例原发性甲状旁腺功能亢进症患者,接受超声引导微波消融辅助持续冷盐水注射治疗;根据疗效分为正常化组和未正常化组,采用Fisher精确检验和Mann-Whitney检验比较两组数据,采用重复测量方差分析分析甲状旁腺激素和血钙水平的时间差异。
诊断标准与关键数值
- 19/22(86.36%)患者甲状旁腺激素和血钙水平均恢复正常。
- 正常化组微波消融后12个月内甲状旁腺激素水平维持正常。
- 未正常化组微波消融后12个月内7次随访中有6次甲状旁腺激素水平超出参考范围。
- 两组所有患者血清钙水平均逐渐下降。
- 治疗后6个月平均血清甲状旁腺激素和平均血钙水平均显著低于微波消融前(均p<0.05)。
临床应用与阅片要点
- 作者认为超声引导微波消融辅助持续冷盐水注射安全有效,可能作为原发性甲状旁腺功能亢进症患者的治疗替代选择。
- 微波消融是高钙血症性或血钙正常性原发性甲状旁腺功能亢进症患者的一种新选择。
- 微波消融可降低甲状旁腺激素和血钙水平,且在多数患者中疗效持续。
- 治疗安全,仅引起暂时性副作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the safety and efficacy of microwave ablation (MWA) with the assistance of continuous cool saline injection (CCSI) in patients with primary hyperparathyroidism (PHPT).
METHODS: Between November 1, 2014, and February 29, 2016, 22 patients with PHPT were enrolled and treated with ultrasound-guided MWA assisted by CCSI. The levels of parathyroid hormone (PTH) and serum calcium were recorded before and after the MWA. Patients were divided into two groups (normalized and unnormalized groups) according to treatment efficacy. Fisher's exact test and the Mann-Whitney test were used to compare data between the two groups. Timing differences in serum PTH and calcium levels were analyzed with repeated measures analysis of variance.
RESULTS: Normalized outcomes for both PTH and calcium levels were achieved in 19 of 22 (86.36%) patients with PHPT. In the normalized group, PTH levels remained normal for 12 months after MWA. PTH levels in the unnormalized group were outside the reference range at six of seven follow-ups within 12 months following MWA. By contrast, serum calcium levels gradually decreased in all patients in both groups. The mean serum PTH and mean calcium levels at 6 months after therapy were significantly lower than those before MWA (both p < 0.05). A transient voice change developed in eight patients. One patient experienced hypocalcaemia, which was corrected by oral calcium supplementation within 2 months.
CONCLUSIONS: US-guided MWA assisted by CCSI is safe and effective for destroying parathyroid gland tissue and may serve as a therapeutic alternative for patients with PHPT.
KEY POINTS: • Microwave ablation is a new option for patients with hypercalcemic or normocalcemic primary hyperparathyroidism. • Microwave ablation can decrease PTH and calcium levels with sustained efficacy in most patients. • Treatment is safe and causes only transient side effects.
引用
- Fan BQ, He XW, Chen HH, et al. US-guided microwave ablation for primary hyperparathyroidism: a safety and efficacy study. Eur Radiol. 2019. PMID: 30888479. doi:10.1007/s00330-019-06078-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。